Inventiva S.A

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of MASH and other diseases in France, the United States, and Internationally. It develops Lanifibranor, for the treatment of patients with metabolic dysfunction-associated steatohepatitis, a progressive, chronic liver disease, which is in Phase III clinical trial; and Odiparcil for the treatment of patients with mucopolysaccharidoses, or MPS, a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was incorporated in 2011 and is headquartered in Daix, France.